Single Agent Ofatumumab Vs. Single Agent Rituximab in Indolent B-Cell Non Hodgkin Lymphoma Relapsed After Rituximab-Containing Therapy

NCT01200589 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

438

Enrollment

INDUSTRY

Sponsor class

Stopped The study stopped due to futility.

Conditions

Non-Hodgkin's Lymphoma

Interventions

BIOLOGICAL: Ofatumumab
BIOLOGICAL: Rituximab
BIOLOGICAL: Ofatumumab
BIOLOGICAL: Rituximab

Sponsor

Novartis Pharmaceuticals

Collaborators

[object Object]